Advances in clinical next-generation sequencing: Target enrichment and sequencing technologies

Expert Review of Molecular Diagnostics

Volumn 16, Issue 3, 2016, Pages 357-372

  Ballester, Leomar Y ^a   Luthra, Rajyalakshmi ^b   Kanagal Shamanna, Rashmi ^b   Singh, Rajesh R ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Next Generation Sequencing; sequencers; target enrichment and cancer genomics; targeted sequencing

Indexed keywords

EXOME; GENETIC MARKER; NEXT GENERATION SEQUENCING; SCREENING; VALIDATION PROCESS; DNA SEQUENCE; HIGH THROUGHPUT SEQUENCING; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PROCEDURES; STANDARDS;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84959376910     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1133298     Document Type: Review

References (85)

1. Cunningham F, Amode MR, Barrell D, et al. Ensembl 2015. Nucleic Acids Res. 2015; 43 (Database issue): D662-669.
2. Clamp M, Fry B, Kamal M, et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci USA. 2007; 104 (49): 19428-19433.
3. Sakharkar MK, Chow VTK, Kangueane P. Distributions of exons and introns in the human genome. In Silico Biol. 2004; 4 (4): 387-393.
4. Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat. 2003; 21 (6): 577-581.
5. Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014; 59 (1): 5-15.
6. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet. 2003; 33 (Suppl): 228-237.
7. Sun Y, Ruivenkamp CA, Hoffer MJ, et al. Next-generation diagnostics: gene panel, exome, or whole genome? Hum Mutat. 2015; 36 (6): 648-655.
8. Mertes F, Elsharawy A, Sauer S, et al. Targeted enrichment of genomic DNA regions for next-generation sequencing. Brief Funct Genomics. 2011; 10 (6): 374-386.
9. Beadling C, Neff TL, Heinrich MC, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn: JMD. 2013; 15 (2): 171-176.
10. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn: JMD. 2013; 15 (5): 607-622.
11. Singh RR, Patel KP, Routbort MJ, et al. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014; 111 (10): 2014-2023.
12. Tewhey R, Warner JB, Nakano M, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol. 2009; 27 (11): 1025-1031.
13. Hedges DJ, Guettouche T, Yang S, et al. Comparison of three targeted enrichment strategies on the SOLiD sequencing platform. PLoS One. 2011; 6 (4): e18595.
14. Peng Q, Vijaya Satya R, Lewis M, et al. Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC Genomics. 2015; 16: 589.
15. Harismendy O, Frazer K. Method for improving sequence coverage uniformity of targeted genomic intervals amplified by LR-PCR using Illumina GA sequencing-by-synthesis technology. Biotechniques. 2009; 46 (3): 229-231.
16. Singh RK, Penny S, Douglas SE. Comparison of next-generation sequencing platforms for clinical testing of non-small cell lung cancer. Pulm Res Respir Med Open J. 2015; 2 (3): 97-108.
17. Tewhey R, Nakano M, Wang X, et al. Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol. 2009; 10 (10): R116.
18. Okou DT, Steinberg KM, Middle C, et al. Microarray-based genomic selection for high-throughput resequencing. Nat Methods. 2007; 4 (11): 907-909.
19. Albert TJ, Molla MN, Muzny DM, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods. 2007; 4 (11): 903-905.
20. Hodges E, Xuan Z, Balija V, et al. Genome-wide in situ exon capture for selective resequencing. Nat Genet. 2007; 39 (12): 1522-1527.
21. Ording GJ, Mercader RJ, Aardema ML, et al. Allochronic isolation and incipient hybrid speciation in tiger swallowtail butterflies. Oecologia. 2010; 162 (2): 523-531.
22. Chen R, Im H, Snyder M. Whole-exome enrichment with the Roche NimbleGen SeqCap EZ exome library SR platform. Cold Spring Harb Protoc. 2015; 2015 (7): pdb prot084855.
23. Chen R, Im H, Snyder M. Whole-exome enrichment with the agilent SureSelect Human All Exon Platform. Cold Spring Harb Protoc. 2015; 2015 (7): pdb prot083659.
24. Chen R, Im H, Snyder M. Whole-exome enrichment with the Illumina TruSeq Exome enrichment platform. Cold Spring Harb Protoc. 2015; 2015 (7): pdb prot084863.
25. Bodi K, Perera AG, Adams PS, et al. Comparison of commercially available target enrichment methods for next-generation sequencing. J Biomol Tech: JBT. 2013; 24 (2): 73-86.
26. Clark MJ, Chen R, Lam Hugo YK, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011; 29 (10): 908-914.
27. Pruitt KD, Brown GR, Hiatt SM, et al. RefSeq: an update on mammalian reference sequences. Nucleic Acids Res. 2014; 42 (Database issue): D756-763.
28. Valencia CA, Rhodenizer D, Bhide S, et al. Assessment of target enrichment platforms using massively parallel sequencing for the mutation detection for congenital muscular dystrophy. J Mol Diagn: JMD. 2012; 14 (3): 233-246.
29. Dahl F, Gullberg M, Stenberg J, et al. Multiplex amplification enabled by selective circularization of large sets of genomic DNA fragments. Nucleic Acids Res. 2005; 33 (8): e71.
30. Dahl F, Stenberg J, Fredriksson S, et al. Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci USA. 2007; 104 (22): 9387-9392.
31. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res. 2005; 15 (2): 269-275.
32. Turner EH, Lee C, Ng SB, et al. Massively parallel exon capture and library-free resequencing across 16 genomes. Nat Methods. 2009; 6 (5): 315-316.
33. Mamanova L, Coffey AJ, Scott CE, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010; 7 (2): 111-118.
34. Johansson H, Isaksson M, Sorqvist EF, et al. Targeted resequencing of candidate genes using selector probes. Nucleic Acids Res. 2011; 39 (2): e8.
35. Berglund EC, Lindqvist CM, Hayat S, et al. Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment. BMC Genomics. 2013; 14: 856.
36. Miya F, Kato M, Shiohama T, et al. A combination of targeted enrichment methodologies for whole-exome sequencing reveals novel pathogenic mutations. Sci Rep. 2015; 5: 9331.
37. Fredriksson S, Baner J, Dahl F, et al. Multiplex amplification of all coding sequences within 10 cancer genes by Gene-Collector. Nucleic Acids Res. 2007; 35 (7): e47.
38. Samorodnitsky E, Datta J, Jewell BM, et al. Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn: JMD. 2015; 17 (1): 64-75.
39. Wang M, Escudero-Ibarz L, Moody S, et al. Somatic mutation screening using archival formalin-fixed, paraffin-embedded tissues by fluidigm multiplex PCR and Illumina sequencing. J Mol Diagn: JMD. 2015; 17 (5): 521-532.
40. Betge J, Kerr G, Miersch T, et al. Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples. PLoS One. 2015; 10 (5): e0127146.
41. Kojima K, April C, Canasto-Chibuque C, et al. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One. 2014; 9 (1): e86961.
42. Chen H, Luthra R, Goswami RS, et al. Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies. Cancers. 2015; 7 (3): 1699-1715.
43. Moens LN, Falk-Sorqvist E, Ljungstrom V, et al. HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples. J Mol Diagn: JMD. 2015; 17 (6): 729-739.
44. Bernard V, Gebauer N, Dinh T, et al. Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples. Int J Clin Exp Pathol. 2014; 7 (4): 1667-1676.
45. Qiu T, Guo H, Zhao H, et al. Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Sci Rep. 2015; 5: 11317.
46. Kanagal-Shamanna R, Portier BP, Singh RR, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014; 27 (2): 314-327.
47. Karnes HE, Duncavage EJ, Bernadt CT. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol. 2014; 122 (2): 104-113.
48. Le Mercier M, DHaene N, De Neve N, et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology. 2015; 66 (2): 215-224.
49. Kirkizlar E, Zimmermann B, Constantin T, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol. 2015; 8 (5): 407-416.
50. Paweletz CP, Sacher A, Raymond CK, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2015 Oct 12. pii: clincanres.1627.2015. [Epub ahead of print]
51. Kurihara S, Ueda Y, Onitake Y, et al. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg. 2015; 50 (12): 2094-2097.
52. Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One. 2014; 9 (8): e103883.
53. Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015; 136 (9): 2158-2165.
54. Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014; 99 (3): 465-473.
55. Schmitt MW, Kennedy SR, Salk JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012; 109 (36): 14508-14513.
56. Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011; 108 (23): 9530-9535.
57. Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015; 61 (1): 64-71.
58. Robison RA. Moores Law: predictor and driver of the silicon era. World Neurosurg. 2012; 78 (5): 399-403.
59. Frey KG, Herrera-Galeano JE, Redden CL, et al. Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood. BMC Genomics. 2014; 15: 96.
60. Hinrichs JW, Van Blokland WT, Moons MJ, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015; 143 (4): 573-578.
61. Quail MA, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012; 13 (1): 341.
62. Koshimizu E, Miyatake S, Okamoto N, et al. Performance comparison of bench-top next generation sequencers using microdroplet PCR-based enrichment for targeted sequencing in patients with autism spectrum disorder. PLoS One. 2013; 8 (9): e74167.
63. Li X, Buckton AJ, Wilkinson SL, et al. Towards clinical molecular diagnosis of inherited cardiac conditions: a comparison of bench-top genome DNA sequencers. PLoS One. 2013; 8 (7): e67744.
64. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet. 2010; 11 (1): 31-46.
65. Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol. 2012; 2012: 251364.
66. Harrington CT, Lin EI, Olson MT, et al. Fundamentals of pyrosequencing. Arch Pathol Lab Med. 2013; 137 (9): 1296-1303.
67. Huang YF, Chen SC, Chiang YS, et al. Palindromic sequence impedes sequencing-by-ligation mechanism. BMC Syst Biol. 2012; 6 (Suppl 2): S10.
68. Eid J, Fehr A, Gray J, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009; 323 (5910): 133-138.
69. Koren S, Harhay GP, Smith TP, et al. Reducing assembly complexity of microbial genomes with single-molecule sequencing. Genome Biol. 2013; 14 (9): R101.
70. Huddleston J, Ranade S, Malig M, et al. Reconstructing complex regions of genomes using long-read sequencing technology. Genome Res. 2014; 24 (4): 688-696.
71. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011; 475 (7356): 348-352.
72. Merriman B, Rothberg JM. Progress in ion torrent semiconductor chip based sequencing. Electrophoresis. 2012; 33 (23): 3397-3417.
73. Suzuki S, Ono N, Furusawa C, et al. Comparison of sequence reads obtained from three next-generation sequencing platforms. PLoS One. 2011; 6 (5): e19534.
74. Li Y, Bare LA, Bender RA, et al. Cost effectiveness of sequencing 34 cancer-associated genes as an aid for treatment selection in patients with metastatic melanoma. Mol Diagn Ther. 2015; 19 (3): 169-177.
75. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013; 15 (9): 733-747.
76. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med: Official J Amer College Med Genet. 2013; 15 (7): 565-574.
77. Aziz N, Zhao Q, Bry L, et al. College of American Pathologists laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015; 139 (4): 481-493.
78. Weiss MM, Van Der Zwaag B, Jongbloed JD, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat. 2013; 34 (10): 1313-1321.
79. Bennett NC, Farah CS. Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers. 2014; 6 (4): 2296-2312.
80. Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009; 133 (5): 743-755.
81. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17 (5): 405-424.
82. Feng Y, Zhang Y, Ying C, et al. Nanopore-based fourth-generation DNA sequencing technology. Genomics Proteomics Bioinf. 2015; 13 (1): 4-16.
83. Steinbock LJ, Radenovic A. The emergence of nanopores in next-generation sequencing. Nanotechnology. 2015; 26 (7): 074003.
84. Wang Y, Yang Q, Wang Z. The evolution of nanopore sequencing. Front Genet. 2014; 5: 449.
85. Rosenstein J. The promise of nanopore technology: nanopore DNA sequencing represents a fundamental change in the way that genomic information is read, with potentially big savings. IEEE Pulse. 2014; 5 (4): 52-54.